New ASX share everyone's ignoring is ready to skyrocket: analysts

Image source: Getty Images
An ASX share that only listed a few weeks ago is being ignored by investors, even though next month’s reporting season could light a fire under it.
That’s according to Wilson Asset Management portfolio managers Matthew Haupt, Catriona Burns and Oscar Oberg, who reckon the pathology services provider has bright long-term prospects.
“
Australian Clinical Labs Ltd (ASX: ACL) continues to benefit from record levels of testing due to the coronavirus, which have extended further given the spread of the more infectious Delta variant,” they wrote in a memo to clients.
“The company has 86 accredited laboratories and services in approximately 90 public and private hospitals.”

Related Keywords

Australia ,Australian ,Matthew Haupt ,Oscar Oberg ,Catriona Burns ,Australian Clinical Labs Ltd ,Capital Limited ,Research Limited ,Australian Clinical Lab ,Wilson Asset Management ,Clinical Labs Ltd ,Australian Clinical ,Clinical Labs ,ஆஸ்திரேலியா ,ஆஸ்திரேலிய ,மேத்யூ ஹோப்ட் ,ஆஸ்கார் ஓபேர்க் ,மூலதனம் வரையறுக்கப்பட்டவை ,ஆராய்ச்சி வரையறுக்கப்பட்டவை ,ஆஸ்திரேலிய மருத்துவ ஆய்வகம் ,வில்சன் சொத்து மேலாண்மை ,ஆஸ்திரேலிய மருத்துவ ,மருத்துவ ஆய்வகங்கள் ,